Optimizing Ajovy Prior Authorization for Gastroenterology Workflows

While Ajovy (fremanezumab) is primarily indicated for migraine prevention and not a typical medication managed within gastroenterology practices, understanding the broader landscape of prior authorization is crucial. Klivira’s platform optimizes prior authorization for gastroenterology workflows, focusing on the high-volume biologics, procedures, and specialty drugs central to GI care.

Gastroenterology practices face significant prior authorization burdens across a diverse range of treatments, from chronic IBD biologics to advanced diagnostic procedures. Managing these complex requirements efficiently is vital for patient access and financial health. Klivira provides a robust solution designed to navigate the specific PA challenges inherent to GI specialty care.

Ajovy and Prior Authorization Landscape

Ajovy (fremanezumab), a CGRP inhibitor, typically requires prior authorization for migraine prevention. While gastroenterologists do not commonly prescribe Ajovy, the underlying mechanisms of prior authorization, including step therapy and medical necessity criteria, are consistent across specialties. Klivira's platform automates these core PA processes, regardless of the specific drug or indication.

Addressing High-Volume Prior Authorization in Gastroenterology

Gastroenterology practices contend with a substantial prior authorization workload, primarily driven by biologics for inflammatory bowel disease (IBD) such as Humira, Stelara, Skyrizi, and Entyvio. Additionally, advanced imaging, specific endoscopic procedures, and specialty drugs for functional GI disorders frequently trigger PA requirements. Efficiently managing these diverse PA categories is critical for maintaining patient care continuity and revenue integrity.

Common Prior Authorization Triggers in GI

IBD biologics (e.g., TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors, JAK inhibitors)
Hepatitis C direct-acting antivirals (DAAs)
Advanced imaging (e.g., MRCP, MR enterography)
Endoscopic procedures with specific PA requirements (e.g., capsule endoscopy)
Specialty drugs for functional GI disorders (e.g., for IBS-D, chronic constipation)
Non-routine colonoscopy surveillance

Navigating GI-Specific Documentation and Clinical Guidelines

Prior authorization for gastroenterology treatments demands precise documentation aligned with established clinical guidelines from bodies like the ACG, AGA, and AASLD. For IBD biologics, this includes diagnosis confirmation, disease severity scores (e.g., Mayo score for UC, CDAI or Harvey-Bradshaw for Crohn's), prior conventional therapy trials, and pre-initiation screenings. Klivira integrates these guideline-driven requirements into its automated workflows, reducing manual review and potential denials.

Mitigating Common GI Prior Authorization Denials

Failure to meet step therapy requirements for IBD biologics
Inadequate documentation of disease severity (e.g., missing Mayo score, CDAI)
Gaps in required pre-treatment screenings (e.g., TB, hepatitis for biologics)
Biosimilar substitution mandates not followed
Insufficient clinical rationale for advanced imaging or capsule endoscopy
Misclassification of treatment-naive vs. treatment-experienced status for Hep C DAAs

Klivira's Comprehensive Prior Authorization Automation for GI

Klivira's platform is specifically engineered to address the intricacies of prior authorization in gastroenterology. We automate the submission process across diverse payer portals and channels, supporting ACG/AGA-guideline-aware step therapy logic for biologics, managing periodic re-authorizations for chronic conditions, and streamlining documentation for medical-vs-pharmacy benefit splits. This reduces administrative burden, accelerates approvals, and enhances patient access to critical GI treatments.

Frequently asked questions

How does Klivira handle step therapy requirements for IBD biologics?

Klivira's platform incorporates ACG and AGA guideline-aware step therapy logic, leveraging EMR integration to automatically identify patient medication history and support compliance with payer-specific requirements for IBD biologics.

Can Klivira manage re-authorizations for chronic GI conditions?

Yes, Klivira includes a dedicated workflow for periodic re-authorization of chronic treatments, such as IBD biologics, ensuring continuous documentation of disease response and timely resubmission to payers, minimizing treatment interruptions.

Does Klivira differentiate between medical and pharmacy benefit for biologics?

Absolutely. Klivira's system is designed to route prior authorization requests appropriately based on whether a biologic is administered under the medical benefit (e.g., infusions) or pharmacy benefit (e.g., self-administered injections), even for the same agent.

How does Klivira help with documentation for Hepatitis C DAAs?

For Hepatitis C direct-acting antivirals, Klivira supports the collection and submission of critical documentation such as genotype, fibrosis stage, prior-treatment history, and drug-drug interaction reviews, streamlining the PA process for these complex therapies.

How does Klivira address denials related to disease severity documentation for IBD?

Klivira prompts for and integrates required disease severity scores like the Mayo score for ulcerative colitis or CDAI for Crohn's disease directly from the EMR, helping ensure that this common denial reason is proactively addressed during the submission process.